Summary of Significant Accounting Policies - Additional Information (Details)		3 Months Ended								12 Months Ended
	Nov. 07, 2022 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2022 USD ($) Customer Segment	Dec. 31, 2021 USD ($) Customer	Dec. 31, 2020 USD ($) Customer
Summary Of Significant Accounting Policies [Line Items]
Restricted cash		$ 5,000,000.0								$ 5,000,000.0
Preferred stock, redemption date										Jul. 31, 2027
Redeemable preferred stock investment		12,385,000				$ 21,965,000				$ 12,385,000	$ 21,965,000
Unrealized gains or losses										$ 9,600,000	2,000,000.0
Number of reporting segments | Segment										1
Number of customer types | Customer										3
Gain from translations										$ (2,665,000)	456,000	$ 20,000
Tax effects related to unrealized holding loss on available-for-sale debt securities										7,200,000	437,000
Tax effects related to unrealized holding gains on available-for-sale debt securities												147,000
Revenue		67,704,000	$ 105,655,000	$ 125,341,000	$ 320,268,000	251,671,000	$ 227,868,000	$ 153,616,000	$ 359,429,000	618,968,000	992,584,000	421,712,000
Contract with customer liability, revenue recognized										$ 14,400,000	26,400,000	$ 257,000
Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations										true
Additional costs expected to be incurred		0								$ 0
Payable balance, expected paid off date										2023-08
Stockholders Equity		$ 1,266,685,000				1,158,749,000				$ 1,266,685,000	1,158,749,000
Cumulative tax effect of accounting change											239,000
Retained Earnings (Accumulated Deficit)
Summary Of Significant Accounting Policies [Line Items]
Cumulative tax effect of accounting change											239,000
Boston Molecules, Inc.
Summary Of Significant Accounting Policies [Line Items]
Ownership percentage		25.00%								25.00%
Carrying value of equity		$ 0				$ 0				$ 0	0
Clinical Insurance Contracts | HSRA COVID-19 Uninsured Program
Summary Of Significant Accounting Policies [Line Items]
Revenue										$ 83,100,000	$ 310,400,000
Insurance Customer
Summary Of Significant Accounting Policies [Line Items]
Percentage of accounts receivable from contract		14.00%				47.00%				14.00%	47.00%
Institutional Customer
Summary Of Significant Accounting Policies [Line Items]
Percentage of accounts receivable from contract		86.00%				53.00%				86.00%	53.00%
Customer Concentration Risk | Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer										1	1	2
Customer Concentration Risk | Revenue | Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage										19.00%	26.00%	28.00%
Customer Concentration Risk | Revenue | Customer Two
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage												10.00%
Customer Concentration Risk | Accounts Receivable, Net | Customer One
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer										1
Concentration risk, percentage										17.00%
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible asset, useful life										14 years
Maximum [Member] | Computer Software
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of fixed assets										5 years
Minimum
Summary Of Significant Accounting Policies [Line Items]
Intangible asset, useful life										5 years
Minimum | Computer Software
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of fixed assets										1 year
Minimum | Customer Concentration Risk | Accounts Receivable, Net
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer											0
Concentration risk, percentage											10.00%
Fulgent Pharma Holdings
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 5,000,000
Revenue	$ 0